Atazanavir: 4 agencies, 2004–2015
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused atazanavir: all 8 decisive outcomes across 4 agencies were positive or positive with restrictions.
Assessment has run over 11 years, from 13 Sep 2004 at SMC (Scotland) to 23 Sep 2015 at HAS (France).
SMC (Scotland) changed its position: restricted on 13 Sep 2004, recommended by 13 Dec 2010.
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2015; on this evidence the file is dormant.
4 distinct indication wordings are recorded for atazanavir by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess atazanavir, on 13 Sep 2004; AWMSG (Wales) did not open a file until 21 Jan 2009 — a wide spread of 4.3 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 8 years in total.
3 of the 4 agencies here assessed atazanavir more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed atazanavir.
The full ledger for atazanavir reads 7 recommended, 4 other and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 23 Sep 2015 | Listing renewal (Transparency Committee) | SMR substantial | source |
| AWMSG (Wales) | 3 Feb 2011 | Co-administered with low dose ritonavir, for the treatment of HIV-1 infected paediatric patients 6 years of age and olde… | recommended (limited) | source |
| SMC (Scotland) | 13 Dec 2010 | Treatment of paediatric patients 6Â years of age and older in combination with other antiretroviral medicinal products | accepted | source |
| PHARMAC (New Zealand) | 15 Feb 2006 | HIV infection | PTAC advice: Medium · decision reached | source |
| SMC (Scotland) | 13 Sep 2004 | HIV | accepted (restricted) | source |
7 further decisions for atazanavir, across 3 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 12 decisions for atazanavir from 4 agencies, 2004 to 2015. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.